Xenotransplantation technology developer eGenesis took its total funding to $263m in a series C round backed by Bayer and Fresenius Medical Care.
US-based gene-editing technology developer eGenesis closed a $125m series C round yesterday that included pharmaceuticals and chemicals producer Bayer and kidney dialysis centre operator Fresenius Medical Care. Bayer subsidiary Leaps by Bayer and Fresnius unit Fresenius Medical Care Ventures were joined by fellow existing investors Arch Venture Partners, Wellington Partners, Khosla Ventures and Alta Partners.…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
